<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896985</url>
  </required_header>
  <id_info>
    <org_study_id>P15-770</org_study_id>
    <nct_id>NCT02896985</nct_id>
  </id_info>
  <brief_title>Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )</brief_title>
  <acronym>PRADA</acronym>
  <official_title>A Cohort Study to Evaluate the Effectiveness of Drug Concentrations in Predicting Recapture of Response With Weekly ADAlimumab in Crohn's Disease Subjects With Secondary Loss of Response (PRADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study that explores the relationship between recapture of response
      with escalation to weekly adalimumab and trough adalimumab concentration before escalation in
      patients experiencing lack of response (LOR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 16, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the relationship between drug concentration at baseline and recapture of response</measure>
    <time_frame>At Week 12</time_frame>
    <description>Logistic regression analysis will be used to model the relationship between drug concentration at baseline and recapture of response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between trough adalimumab concentrations at baseline and change in patient reported outcome 2 (PRO2)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Covariance analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between trough adalimumab concentrations at baseline and change in C-reactive protein (CRP)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Covariance analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between trough adalimumab concentrations at baseline and change in fecal calprotectin</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Covariance analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring steroids or additional therapy</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Assessing participants that require steroids or additional therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with 50% drop from screening in CRP or calprotectin</measure>
    <time_frame>At Week 12</time_frame>
    <description>Assessing participants with 50% drop in CRP or calprotectin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between changes in HBI between screening and final trough adalimumab concentrations</measure>
    <time_frame>At Week 12</time_frame>
    <description>Covariance analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinical remission PRO2 &lt; 8</measure>
    <time_frame>At Week 12</time_frame>
    <description>PRO2 was developed based on FDA guidance for use of patient reported outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with normalization of CRP or fecal calprotectin</measure>
    <time_frame>At Week 12</time_frame>
    <description>Assessing participants with normalization of CRP (&lt;5mg/dl) or fecal calprotectin (&lt;150ug/ml)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Participants with Crohn's disease</arm_group_label>
    <description>Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be enrolled from approximately 15 to 20 investigative sites in Canada
        where such Therapeutic Drug Monitoring/Anti-Adalimumab Antibody (TDM/AAA) testing at the
        point of patient LOR and pre-dose escalation to Every Week (EW) occurs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of Crohn's Disease.

          -  Treatment with adalimumab, for a minimum of 16 weeks, as per clinical practice, at a
             dose of 160 mg at week 0, 80 mg at week 2, and then 40 mg q2w with a documented
             response as defined by the investigator.

          -  Current evidence of active inflammatory disease/LOR defined as the presence of active
             inflammation (confirmed with a CRP ≥ 5 mg/L and/or a fecal calprotectin ≥ 250µg/g.

          -  Ability of subject to participate fully in all aspects of this clinical trial.

          -  Written informed consent must be obtained and documented.

        Exclusion Criteria:

          -  Primary non-responders to 16 weeks of adalimumab therapy.

          -  Received any investigational drug within the 16 weeks of adalimumab therapy.

          -  Serious underlying disease other than CD that, in the opinion of the investigator, may
             interfere with the subject's ability to participate fully in the study.

          -  History of alcohol or drug abuse that, in the opinion of the investigator, may
             interfere with the subject's ability to comply with the study procedures.

          -  Stools positive for Clostridium difficile.

          -  Pregnant or lactating women.

          -  Current enrolment in any other interventional research study.

          -  Presence of perianal or abdominal abscess.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Foucault</last_name>
    <phone>5148327702</phone>
    <email>nathalie.foucault@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Charbonneau</last_name>
    <phone>5148327197</phone>
    <email>julie.charbonneau@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Edmonton Gastroenterolog</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 6K3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Gastro Mgmnt Ltd</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Everett Chalmers Reg Hosp.</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 5N5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qe Ii Hsc</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Mark Lee Medicine Professi</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 0B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Med Cent</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jeffrey So Medicine Professional Corporation</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taunton surgical centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Digestive Disease Asso</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr O Tarabain Medicine Prof Corp</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Rahman Bacchus Med. Corp.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8Y 4C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CISSS de la Monteregie</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel-Dieu de Levis</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique MEDI-CLE</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Uni Saskatchew(CTSU)</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient Reported Outcome 2 (PRO 2)</keyword>
  <keyword>C-Reactive Protein (CRP)</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Harvey Bradshaw Index (HBI)</keyword>
  <keyword>Therapeutic Drug Monitoring (TDM)</keyword>
  <keyword>Anti-Adalimumab Antibody (AAA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

